Summary Low-dose fractionated y-irradiation (three cycles of 5 x 2 Gy) induced cisplatin resistance in HeLa cells. The drug resistance was modest (Rf of about 2) and stable, similar to that found previously in murine cells after irradiation. In the drug-resistant HeLa-C3 cells, flow cytometric analysis revealed a decreased number of apoptotic cells compared with the parental cells. Drug resistance was associated with considerably enhanced expression of the p53 suppressor protein in HeLa-C3 cells after cisplatin exposure but seemed not to be regulated by the bcl-2-dependent pathway. Cisplatin resistance correlated with reduced expression of ICE-related proteases (interleukin-1 n-converting enzyme). Basal levels of the 45-kDa precursor ICE protein were reduced in HeLa-C3 cells, while those of the mature 60-kDa heterotetramer were similar. The CPP32 protease, a member of the ICE family with structural homology but different substrate specificity, was expressed at a lowered level. After drug exposure, there was a slight increase of CPP32 in HeLa-C3 cells, equivalent to about 45% of the level attained in the parental cells. This is in contrast to the CPP32 levels measured after irradiation, which were similar in sensitive and in resistant cells. As the radiosensitivity is unchanged in both cell lines, these results suggest that cisplatin resistance in HeLa-C3 cells is associated with alterations of a CPP32-linked apoptotic pathway, which is affected by the damage caused by cisplatin but not by irradiation. Whether these changes are dependent on the observed p53 modifications is now being studied in resistant clones.
We have recently shown that cisplatin resistance is induced in murine fibrosarcoma cells by low-dose fractionated y-irradiation. Resistance was associated with alterations of the cGMP-dependent transduction pathway and could be overcome either by enhanced cGMP formation (Eichholtz-Wirth, 1995a) or by heat (EichholtzWirth, 1995b) . It was of interest to investigate whether a similar resistance could also be induced by radiation in human cells. In the following study, radiation-induced cisplatin resistance is described after fractionated y-irradiation in HeLa cells. The mechanisms of resistance, which were different to those described for the murine cells (Eichholtz-Wirth et al, 1993 , 1994 , were associated with altered expression of interleukin-converting enzyme (ICE)-related proteases.
The ICE-like proteins belong to a class of cysteine proteases that play a key role in apoptosis. ICE was synthesized as inactive 45-kDa precursor protein, which was processed proteolytically to yield a large (p20) and a small (plO) subunit (Thomberry et al, 1992 ; Wilson et al, 1994) . These generated the biologically active 60-kDa heterotetramer either by autoprocessing or by coassembling with other family members or with unrelated proteases. Different ICE transcripts have been identified (Alnemri et al, 1995) that encode catalytically inactive or truncated isoforms that are able to coassemble and to yield inactive proteases.
Based on their sequence homology, the members of the ICE family may be divided in two major subgroups: one with greater homology to ICE (such as Nedd-2, Ich-1; Wang et al, 1994; Faucheau et al, 1995) , the other to CPP32 (such as Mch-2; Femandes- Alnemri et al, 1994; Nicholson et al, 1995; Chen et al, 1996) . The various ICE-like proteases are characterized by different substrate specificity and may be specifically inhibited (Bump et al, 1995; Tewari et al, 1995a) . Their activation and mechanisms of regulation are complex and only poorly understood.
Overexpression of ICE-like proteases has been demonstrated to induce apoptosis (Miura et al, 1993; Fernandes-Alnemri et al, 1994; Faucheau et al, 1995) . In the present study, altered expression of ICE-like proteases is shown to inhibit apoptosis and to be a mediator of cellular resistance to cisplatin after radiation treatment.
MATERIALS AND METHODS

Materials
The following drugs and chemicals were used: cisplatin solution (Medac, Hamburg); vincristine (Lilly), doxorubicin (Farmitalia), etoposide (Bristol), Eagle's minimal essential medium (Serva); bycomycin (Byc Gulden, Konstanz); newborn calf serum (CCPro, Karlsruhe); all other chemicals were purchased from Sigma Chemie, Deisenhofen.
For the Western blot analysis, the following antibodies were used: precICE and ICE, plO(C-20) rabbit PAb (Santa Cruz); p53 DO-7 and bcl-2, mouse MAb (Dako); CPP32, mouse MAb (Transduction Laboratories).
Cell culture
HeLa and HeLa-C3 cells were grown as monolayer cultures in Eagle's minimal medium, containing L-glutamine and supplemented with 10% newborn calf serum, 0.01% bycomycin and 0.035% sodium bicarbonate and maintained at 37°C at pH 7.4 in a controlled atmosphere (3-3.5% carbon dioxide in air).
For the induction of cisplatin resistance, exponentially growing HeLa cells were subjected to a cycle of fractionated 137CS irradiation (5 x 2 Gy in 7 days). The cells were then subcultured once per week over 4-6 weeks with parallel checking of drug sensitivity. If the drug sensitivity was unchanged, the treatment protocol was repeated. The preirradiated cells were denoted Cl, C2, C3, according to the number of treatment cycles.
Determination of drug and radiation sensitivity
To establish cisplatin survival curves, exponentially growing cells were appropriately diluted and allowed to attach to the glass surface overnight. The drugs were freshly diluted in Hanks' solution and added to the culture medium. After a 1-h exposure period, the medium was withdrawn, the cells rinsed with Hanks' solution and fresh culture medium was added. To assess cross-resistance, cell survival to the following drugs was determined after continuous exposure: cadmium chloride (stock solution 10 mm in water), vincristine liquid (1 mg ml-1 vincristine sulphate), doxorubicin (2 mg ml' injection solution, Farmitalia), etoposide (20 mg ml' infusion concentrate, Bristol). To generate radiation survival curves, cells were exposed to graded single doses of y-rays from a Gammacell 40 caesium-137 source at a dose rate of 1.2 Gy min-'. After 7-9 days of incubation, all flasks were stained and scored for colonies of 50 or more cells. The surviving fraction (SF) was corrected for the plating efficiency of untreated cells.
Resistance factors (Rf) were calculated from the ICIO values of the survival curves. The ICIO is the drug concentration at a given exposure time required to reduce cell survival to 10%. Data from cell survival experiments are means of at least three independent experiments. Standard deviation bars are shown except when the error is less or equal to the symbol size. P-values are given for statistical significance between various treatment procedures; values less than 0.05 were considered to be statistically significant.
Flow cytometry
All FACS measurements required a cell number of 0.5 x 106. For the cell cycle analysis, the nuclei were prepared according to the method developed by Nuisse and Kramer (1984) . The tissue culture medium was collected, combined with the trypsinized cells and centrifuged for 7 min at 100g. After removing the supermatant completely, the cell pellet was slightly shaken. The cells were first incubated for 30 min with 1 ml of solution I (584 mg 1-' sodium chloride, 1 g 1-sodium citrate, 10 mg 1-RNAase, 0.3 ml of Nonidet P40 and 25 mg 1-ethidium bromide) at room temperature and after another 30 min, 1 ml of solution II was added (15 g 1-' citric acid, 0.25 M sucrose and 40 mg 1-' ethidium bromide). Until use, samples could be stored in the dark at 4°C for at least 1-2 weeks.
For the measurement of apoptotic cells, the Annexin-V-Fluos Kit from Boehringer Mannheim was used. The preparation, staining and measurement of the cells was carried out according to the manufacturer's instruction.
The cells were analysed in a FACStar+ cell sorter (Becton Dickinson), equipped with two argon ion lasers (Innova 90, Coherent). All dyes were excited with the 488-nm line. Ethidium bromide (EB) and propidium iodide (PI) fluorescence were detected at wavelengths above 590 nm. Fluorescein (FITC) fluorescence was detected by a bandpass filter at 530 nm. For each sample, 20 000 events were acquired. All parameters were recorded in logarithmic scale and the data were analysed with the Data Analysis System (DAS) software developed by Beisker (1994) .
Western blot analysis
Approximately 2 x 106 cells were detached from the glass surface, washed with phosphate-buffered saline (PBS) and centrifuged. Before separation, the probes were heated at 90°C for 5 min, resolved on SDS-polyacrylamide gels (10-12%) and transferred on a polyvinyldifluoride (PVDF) membrane in TBS-T buffer (20 mm Tris, 137 mm sodium chloride, 1 M hydrochloric acid, 0.1% Tween 20). After blocking with 5% skimmed milk, the membranes were exposed to the primary antibody (1 jg ml-', ON). The filters were washed with TBS-T followed by incubation with the second antibody for 2 h at room temperature. The filters were washed again and then developed. The detection was accomplished with the enhanced chemiluminescence (ECL) method. The western blots were analysed using Pharmacia Biotech software Image Master ID.
RESULTS
After three cycles of fractionated y-radiation treatment, HeLa cells developed a moderate cisplatin resistance (Rf = 2.1), which had been stable for more than 150 cell generations (Figure 1 ). The drug-resistant HeLa-C3 cells exhibited similar doubling times as HeLa cells (20.5-23 h) and a similar protein content (175-195 ,ug 0I cells) . HeLa-C3 cells slightly changed their phenotype with more polyhedric morphology compared with the more elongated shape of the parental cells. As in murine cells after y-irradiation, there was no cross-resistance to irradiation (Figure 2) . Also, the sensitivity to doxorubicin and etoposide was unchanged, whereas the sensitivity to vincristine was enhanced (Table 1) . Metallothioneins were unaltered, as evidenced by the identical toxicity to cadmium (an indirect measure of metallothioneins).
By flow cytometric cell cycle analysis, no differences between Hela and HeLa-C3 cells were found. The analysis of apoptotic cells with the Annexin-V-Fluos Kit was based on plasma membrane alterations occurring during the apoptotic process. Phosphatidylserine (PS) is translocated to the outer leaflet of the plasma membrane and can thus be detected by the fluoresceinlabelled protein Annexin-V, which has a high affinity for PS. Figure 3A demonstrates the differences in the number of apoptotic cells in both populations 48 h after cisplatin exposure (0.5 or 5.0 jig ml-for 1 h) and 48 h after y-irradiation (7.5 Gy). In the parental HeLa cells, there was a considerable increase in apoptotic cells from 4.8 ± 1.4% (control) to 27.1 ± 2.2% after the low and to 58.6 ± 7.3% after the high drug dose; in the resistant HeLa-C3 cells, this increase was significantly ,lower (7.5 ± 1.5% and 30.6 ± 10.6% respectively). A time-course study also revealed differences in the entry into apoptosis between both cell lines ( Figure 3B) . In Hela cells, the number of apoptotic cells increased continuously after cisplatin exposure and reached a plateau after British Joumal of Cancer (1997) HeLa-C3 Figure 4 Expression of apoptosis-related proteins in HeLa and HeLa-C3 cells after cisplatin exposure. Western blot analysis was performed before (controls, El) and 24 h after a 1-h cisplatin exposure (5 9g ml-1, E), using the following proteins: p53 (A), bcl-2 (B) and the 45-kDa ICE precursor protease (C). Mean relative chemiluminescence ± s.d. of three or more experiments 48 h. In the resistant population, a significant increase in apoptotic cells was observed only 48 h after drug exposure. However, in HeLa-C3 cells, the variation was high and the increase after 18 h was not significant. After y-irradiation, the number of apoptotic cells remained below 10% in both cell lines after 24 h (not shown) and 48 h ( Figure 3A) .
One of the main regulatory proteins involved in apoptosis and also associated with cisplatin resistance (Kastan et al, 1992; Tishler et al, 1993 ) is the p53 protein. Basal levels of this protein are low in HeLa and HeLa-C3 cells (Figure 4 ). Twenty-four hours after a 1-h cisplatin exposure, about threefold higher p53 protein levels were found in the resistant compared to the parental cells. 30 h post drug exposure ( Figure 5 ). At 48 h, the protein level had almost declined in both cell lines. After irradiation (24 h after 7.5 Gy), the suppressor protein was also expressed at a higher rate in HeLa-C3 cells. Among the p53-dependent apoptotic proteins, increased bcl-2 formation may be associated with drug resistance. As the expression of this anti-apoptotic protein is slightly reduced in HeLa-C3 compared with HeLa cells (Figure 4 ) and as differences in stability seem to be small ( protein expression persisted. Basal levels of the catalytically active 60-kDa heterotetramer were similar in both cell lines (relative chemiluminescence 9.0 for HeLa and 8.7 for HeLa-C3 cells). The protease CPP32, a member of the ICE family, displayed considerably lower basal protein levels in the resistant HeLa-C3 cells. After cisplatin treatment, CPP32 increased in both cell lines, but only about 45% of the protease level, measured in the parental cells, was attained in the resistant population ( Figure 6 ). After irradiation (24 h after 7.5 Gy), the same expression of CPP32 protein was found in both cell lines.
DISCUSSION
ICE-related proteases play a central role in the induction and execution of apoptosis. Their additional importance in the regulation of apoptosis was demonstrated in our study. Alteration of the expression of ICE-related proteases is associated with the development of cellular resistance in HeLa-C3 cells. CPP32, a member of the ICE family, which is expressed at a reduced rate in HeLa-C3 cells, is probably differentially affected or regulated by the type of insult or damage involved. The signalling pathway and/or the DNA cross-linking damage caused by cisplatin induces a lower CPP32 level in HeLa-C3 cells. Radiation damage that finally leads to single-and double-strand breaks results in similar CPP32 protein expression in HeLa and HeLa-C3 cells, in accordance with their identical cellular radiosensitivity. The induction and regulation of the apoptotic pathway is complex and only poorly understood. The growing family of ICE-related proteases are involved in the death-signalling pathways in an intricate pattem of cooperation and interaction. These proteases are characterized by structural homology and different, but overlapping, substrate specificity (Femandes-Alnemri et al, 1994; Faucheau et al, 1995; Nicholson et al, 1995; Tewari et al, 1995b) . Whether the various isoforms act in parallel or sequentially and how their signal is amplified -a process necessary for rapid apoptosis -is still unknown. Moreover, not all the activation processes that have been demonstrated in vitro may be relevant in vivo (Enari et al, 1995) . In HeLa-C3 cells, lower basal levels of preICE (but not of the mature ICE) and reduced levels of CPP32 after cisplatin exposure (but not after irradiation) were demonstrated to be involved in the regulation of cisplatin resistance. However, there are probably far more proteases that are altered and that may affect the signalling pathway of cisplatin repair. CPP32 is synthesized as an inactive precursor; the mature protease is generated by autocatalysis or by other proteases, such as ICE (Fernandez-Alnemri et al, 1994; Tewari et al, 1995b) . CPP32 is supposed to act downstream of ICE, suggesting that reduced induction of CPP32 in HeLa-C3 cells may be associated with decreased activation due to the low precursor ICE protein levels in these cells. The mature protein can also be formed from truncated or mutant subunits, such as ICEe, which are efficiently transcribed, translated and folded and which act as dominant inhibitors of ICE activity (Wilson et al, 1994; Alnemri et al, 1995) . If such mutant proteins are also formed under physiological conditions or in response to stress, they may alter or inactivate the apoptotic pathway, as in HeLa-C3 cells. Therefore, the unchanged expression of the mature 60-kDa ICE protein in HeLa-C3 cells does not provide evidence about the activity of the protein. A correlation of protein expression and enzyme activity in HeLa and HeLa-C3 cells will be the subject of further experimental study. Viral inhibitors of CPP32 have been described, such as the cytokine response modifier A (CrmA) (Miura et al, 1993; Tewari and Dixit, 1995) or the baculovirus gene product p35 (Bump et al, 1995) . However, it is not known whether there are cellular homologues of these viral inhibitors of ICE-like proteases that might also be involved in the induction of cellular drug resistance in HeLa-C3 cells.
One of the possible substrates for CPP32 is PARP, an enzyme that is involved in DNA repair and genomic surveillance and integrity (Nicholson et al, 1995; Tewari et al, 1995b) . At the onset of apoptosis, PARP is proteolytically cleaved, which highly activates an endonuclease implicated in intemucleosomal DNA cleavage. In HeLa-C3 cells, the substrates are not known. It is speculated that the DNA-cross-linking damage, induced by cisplatin, could involve repair proteins, such as the high-mobility group protein (HMG) (Billings et al, 1992; Chow et al, 1995) .
These transcription factors function as activators/repressors of transcriptional regulation by enhanced binding to target promotor sequences. Overexpression of damage recognition proteins, also a possible substrate of ICE-related proteins, has been implicated in cisplatin resistance in HeLa cells (Chao et al, 1991) .
Reduced expression of the ICE-related proteases correlates with reduced induction of apoptosis. After cisplatin exposure, the number of apoptotic cells is considerably lower in the drug-resistant than in the parental cells. There is evidence that the p53 suppressor protein affects the induction of apoptosis; however, only some, not all, apoptotic pathways are p53-dependent. Wild gives rise to an uncloned heterogeneous population. More detailed studies on the involvement of altered p53 in the regulation of cisplatin resistance in HeLa-C3 cells will now be initiated using single isolated clones to avoid interfering or overlapping effects. One of the various p53-dependent proteins that is implicated in apoptosis is the bcl-2 protein. In HeLa-C3 cells, this protein does not seem to be associated with the regulation of cisplatin resistance. This anti-apoptotic protein remains at similar or slightly reduced levels in the resistant HeLa-C3 compared with the parental HeLa cells. Also, regulatory functions described for bcl-2 in the suppression of ICE proteins (Miura et al, 1993 ) may therefore not operate in cisplatin resistance in HeLa-C3 cells. However, bcl-2 is only one of several anti-apoptotic proteins in this death pathway, and it would be interesting to know whether other family members (such as bcl-xL) are involved or whether the ratio of proand anti-apoptotic proteins is changed. Again, as mentioned above for the p53 data, modified protein expression of individual clones may be masked in these experiments.
Our present study was planned to investigate the development of cisplatin resistance of an uncloned human cell population after fractionated y-irradiation and to determine which cell death pathways are altered. More detailed studies on the mechanisms of resistance will now be carried out with individual resistant clones.
In summary, we conclude that low-dose y-irradiation induces moderate, but stable, cisplatin resistance in HeLa cells. Drug resistance is associated with increased levels of p53 protein and decreased levels of ICE-related proteases. As the response to radiation is unaltered both in terms of cell survival and CPP32 expression, the results suggest that CPP32 is involved in the signalling cascade of the death pathway initiated by cisplatin but not radiation damage.
